KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Amortization - Intangibles: 2019-2025

Historic Amortization - Intangibles for Supernus Pharmaceuticals (SUPN) over the last 7 years, with Sep 2025 value amounting to $24.3 million.

  • Supernus Pharmaceuticals' Amortization - Intangibles rose 24.74% to $24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.2 million, marking a year-over-year increase of 2.95%. This contributed to the annual value of $78.0 million for FY2024, which is 5.34% down from last year.
  • As of Q3 2025, Supernus Pharmaceuticals' Amortization - Intangibles stood at $24.3 million, which was up 16.84% from $20.8 million recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Amortization - Intangibles ranged from a high of $24.3 million in Q3 2025 and a low of $5.9 million during Q2 2021.
  • Moreover, its 3-year median value for Amortization - Intangibles was $20.1 million (2024), whereas its average is $20.5 million.
  • Its Amortization - Intangibles has fluctuated over the past 5 years, first soared by 362.08% in 2021, then decreased by 13.36% in 2024.
  • Over the past 5 years, Supernus Pharmaceuticals' Amortization - Intangibles (Quarterly) stood at $12.0 million in 2021, then spiked by 71.97% to $20.7 million in 2022, then climbed by 1.86% to $21.1 million in 2023, then declined by 13.36% to $18.3 million in 2024, then climbed by 24.74% to $24.3 million in 2025.
  • Its last three reported values are $24.3 million in Q3 2025, $20.8 million for Q2 2025, and $19.8 million during Q1 2025.